Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2

Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2

There is considerable interest in tankyrase because of its potential use in cancer therapy. Tankyrase catalyzes the ADP-ribosylation of a variety of target proteins and regulates various cellular processes. The anti-cancer effects of tankyrase inhibitors are mainly due to their suppression of Wnt si...

Full description

Bibliographic Details
Main Authors: Tomoyuki Mukai, Shunichi Fujita, Yoshitaka Morita
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Cells
Subjects:
tankyrase
PARP5
tankyrase inhibitor
SH3BP2
cherubism
osteoclast
osteoblast
osteopenia
PARP1
Online Access:https://www.mdpi.com/2073-4409/8/2/195

Similar Items

Similar Items